{"entity":{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","aka":[],"tldr":"Leads the German Hodgkin Study Group and HD21, which made BrECADD the most effective and least toxic regimen for advanced Hodgkin lymphoma.","summary":"Peter Borchmann chairs the German Hodgkin Study Group and was principal investigator of HD21, which showed the brentuximab-based BrECADD regimen is both more effective and less toxic than escalated BEACOPP in advanced-stage Hodgkin lymphoma with 95% three-year progression-free survival, and of HD18, which used PET to reduce treatment from six cycles to four. He leads GHSG trials of immunotherapy in first-line disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Borchmann%20P%5BAuthor%5D%20Hodgkin"}],"tags":["hodgkin","ghsg","trialist"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":["adc","fdg-pet"],"targets":[],"drugs":["brentuximab-vedotin"],"companies":["ghsg"],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["hd21"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Head of the German Hodgkin Study Group, University Hospital Cologne","institutionId":"uniklinik-koeln","specialisms":["Hodgkin lymphoma","PET-guided therapy","Antibody-drug conjugates","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Borchmann%20P%5BAuthor%5D%20Hodgkin"}],"papers":[{"title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)01315-1"},{"title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)32134-7"}]},"route":"/people/peter-borchmann/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"}],"company":[{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","route":"/companies/ghsg/"}],"institution":[{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/"}],"trial":[{"id":"hd10","kind":"trial","name":"GHSG HD10","route":"/trials/hd10/"},{"id":"hd16","kind":"trial","name":"GHSG HD16","route":"/trials/hd16/"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/"},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/"}],"paper":[{"id":"paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017","kind":"paper","name":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/"},{"id":"paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019","kind":"paper","name":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}